Tricuspid Valve Disease clinical trials at University of California Health
3 in progress, 1 open to eligible people
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
open to eligible people ages 18 years and up
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
at UC Irvine UCLA UCSF
TRISCEND II Pivotal Trial
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
Sorry, in progress, not accepting new patients
Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system
at UC Davis UCSF
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
Sorry, not currently recruiting here
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system is a single use, sterile device compatible with all the valve sizes. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system.
at UCSF
Our lead scientists for Tricuspid Valve Disease research studies include Marcella Press, MD Antonio Frangieh, MD Sammy Elmariah, MD.
Last updated: